The first Brain Foundation annual symposia, Pleasanton, California 8-10 of Nov 2019, aimed to connect researchers with clinicians, donors & stake holders to help translate research efforts into evidence-based treatments for autism and its co-morbidities. It highlighted the need for multidisciplinary collaboration, detailed diagnostics and personalised treatment…
The Thinking Autism conference blends the opportunity to quench my thirst for autism knowledge, attend accessible social events where I can meet those unique individuals I have built a friendship with online, and the necessary support from dedicated members of the Thinking Autism team, all of whom have a lifetime of first-hand autism experience.
Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome, Neurofibromatosis Type 1 suffer high rates of autism. Everolimus, an mTOR inhibitor with strong neuro-inflammation attenuating effects, reduces core autism symptoms in some children with TSC, epilepsy and autism…
Babies who are exposed to perinatal complicatios incl. asphyxia, preeclampsia, and meconium-stained amniotic fluid, are at increased risk of developing autism. The risk is especially high for babies exposed to complications both before and during birth.
Keep informed - subscribe to our mailing list
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Privacy Policy | Terms and Conditions
© 2019 Thinking Autism | All rights reserved | Registered Charity: No. 1113628, Limited Company Registered in England: No. 5594787 | Registered address: International House, 24 Holborn Viaduct, London, EC1A 2BN | Contact tel. 07518131697